Paediatric and adult malignant glioma: Close relatives or distant cousins?

Nature Reviews Clinical Oncology

Volumn 9, Issue 7, 2012, Pages 400-413

  Jones, Chris ^a   Perryman, Lara ^b   Hargrave, Darren ^c  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c GREAT ORMOND STREET HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLIN DEPENDENT KINASE INHIBITOR 2B; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; LOMUSTINE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PREDNISONE; PROTEIN P53; TEMOZOLOMIDE; VINCRISTINE;

AGE DISTRIBUTION; BRAF GENE; CANCER COMBINATION CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER GRADING; CANCER LOCALIZATION; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CDKN2A GENE; CDKN2B GENE; CHROMOSOME MARKER; DRUG EFFICACY; EGFR GENE; GENE DOSAGE; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; GLIOBLASTOMA; HISTOPATHOLOGY; HUMAN; IDH1 GENE; IDH2 GENE; MOLECULAR PATHOLOGY; MUTATIONAL ANALYSIS; MUTATOR GENE; NEUROPATHOLOGY; NONHUMAN; ONCOGENE; OVERALL SURVIVAL; PDGFRA GENE; POINT MUTATION; PONTINE GLIOMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; REVIEW;

ADULT; AGE FACTORS; BRAIN NEOPLASMS; CHILD; GLIOMA; HUMANS; PROGNOSIS;

EID: 84863434843     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2012.87     Document Type: Review

References (176)

1. Bailey, P. & Cushing, H. A. A classification of the tumours of the glioma group on a histogenetic basis, with a correlated study of prognosis (J. B. Lippincott, Philadelphia, 1926).
2. Louis, D. N. et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 114, 97-109 (2007).
3. Daumas-Duport, C., Scheithauer, B., O'Fallon, J. & Kelly, P. Grading of astrocytomas. A simple and reproducible method. Cancer 62, 2152-2165 (1988).
4. Gilles, F. H. et al. Limitations of the World Health Organization classification of childhood supratentorial astrocytic tumors. Children Brain Tumor Consortium. Cancer 88, 1477-1483 (2000).
5. Brown, W. D. et al. Prognostic limitations of the Daumas-Duport grading scheme in childhood supratentorial astroglial tumors. J. Neuropathol. Exp. Neurol. 57, 1035-1040 (1998).
6. Puget, S. et al. Neuropathological and neuroradiological spectrum of pediatric malignant gliomas: correlation with outcome. Neurosurgery 69, 215-224 (2011).
7. Arora, R. S. et al. Age-incidence patterns of primary CNS tumors in children, adolescents, and adults in England. Neuro. Oncol. 11, 403-413 (2009).
8. Rineer, J., Schreiber, D., Choi, K. & Rotman, M. Characterization and outcomes of infratentorial malignant glioma: a population-based study using the Surveillance Epidemiology and End-Results database. Radiother. Oncol. 95, 321-326 (2010).
9. Central Brain Tumor Registry of the United States. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2004-2007 [online], http://www.cbtrus.org/2011-NPCR-SEER/WEB-0407- Report-3-3-2011.pdf (2011).
10. Soffietti, R. et al. Guidelines on management of low-grade gliomas: report of an EFNS-EANO Task Force. Eur. J. Neurol. 17, 1124-1133 (2010).
11. Broniscer, A. et al. Clinical and molecular characteristics of malignant transformation of low-grade glioma in children. J. Clin. Oncol. 25, 682-689 (2007).
12. Qaddoumi, I., Sultan, I. & Gajjar, A. Outcome and prognostic features in pediatric gliomas: a review of 6212 cases from the Surveillance, Epidemiology, and End Results database. Cancer 115, 5761-5770 (2009).
13. Hargrave, D., Bartels, U. & Bouffet, E. Diffuse brainstem glioma in children: critical review of clinical trials. Lancet Oncol. 7, 241-248 (2006).
14. Kramm, C. M. et al. Thalamic high-grade gliomas in children: a distinct clinical subset? Neuro. Oncol. 13, 680-689 (2011).
15. Wolff, J. E. et al. Subpopulations of malignant gliomas in pediatric patients: analysis of the HIT-GBM database. J. Neurooncol. 87, 155-164 (2008).
16. Wolff, B. et al. Pediatric high grade glioma of the spinal cord: results of the HIT-GBM database. J. Neurooncol. 107, 139-146 (2012).
17. Finlay, J. L. et al. Randomized phase III trial in childhood high-grade astrocytoma comparing vincristine, lomustine, and prednisone with the eight-drugs-in-1-day regimen. Childrens Cancer Group. J. Clin. Oncol. 13, 112-123 (1995).
18. Barrow, J. et al. Homozygous loss of ADAM3A revealed by genome-wide analysis of pediatric high-grade glioma and diffuse intrinsic pontine gliomas. Neuro. Oncol. 13, 212-222 (2011).
19. Bax, D. A. et al. A distinct spectrum of copy number aberrations in paediatric high grade gliomas. Clin. Cancer Res. 16, 3368-3377 (2010).
20. Paugh, B. S. et al. Integrated molecular genetic profiling of pediatric high-grade gliomas reveals key differences with the adult disease. J. Clin. Oncol. 28, 3061-3068 (2010).
21. Puget, S. et al. Integrated genomics indentifies three high-grade glioma subtypes with distinct genetic profiles, pathway signatures, and clinicopathological features. Neuro. Oncol. 12, i11 (2010).
22. Qu, H. Q. et al. Genome-wide profiling using single-nucleotide polymorphism arrays identifies novel chromosomal imbalances in pediatric glioblastomas. Neuro. Oncol. 12, 153-163 (2010).
23. Schiffman, J. D. et al. Oncogenic BRAF mutation with CDKN2A inactivation is characteristic of a subset of pediatric malignant astrocytomas. Cancer Res. 70, 512-519 (2010).
24. Wong, K. K. et al. Genome-wide allelic imbalance analysis of pediatric gliomas by single nucleotide polymorphic allele array. Cancer Res. 66, 11172-11178 (2006).
25. Schwartzentruber, J. et al. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature 482, 226-231 (2012).
26. Wu, G. et al. Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. Nat. Genet. 44, 251-253 (2012).
27. Johnson, R. A. et al. Cross-species genomics matches driver mutations and cell compartments to model ependymoma. Nature 466, 632-636 (2010).
28. Li, M. et al. Frequent amplification of a chr19q13.41 microRNA polycistron in aggressive primitive neuroectodermal brain tumors. Cancer Cell 16, 533-546 (2009).
29. Perry, A. et al. Malignant gliomas with primitive neuroectodermal tumor-like components: a clinicopathologic and genetic study of 53 cases. Brain Pathol. 19, 81-90 (2009).
30. Zarghooni, M. et al. Whole-genome profiling of pediatric diffuse intrinsic pontine gliomas highlights platelet-derived growth factor receptor α and poly (ADP-ribose) polymerase as potential therapeutic targets. J. Clin. Oncol. 28, 1337-1344 (2010).
31. McLendon, R. et al. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455, 1061-1068 (2008).
32. Parsons, D. W. et al. An integrated genomic analysis of human glioblastoma multiforme. Science 321, 1807-1812 (2008).
33. Bax, D. A. et al. EGFRvIII deletion mutations in pediatric high-grade glioma and response to targeted therapy in pediatric glioma cell lines. Clin. Cancer Res. 15, 5753-5761 (2009).
34. Geoerger, B. et al. Innovative Therapies for Children with Cancer pediatric phase I study of erlotinib in brainstem glioma and relapsing/refractory brain tumors. Neuro. Oncol. 13, 109-118 (2011).
35. Cheng, Y. et al. Genetic alterations in pediatric high-grade astrocytomas. Hum. Pathol. 30, 1284-1290 (1999).
36. Jha, P. et al. Heterozygosity status of 1p and 19q and its correlation with p53 protein expression and EGFR amplification in patients with astrocytic tumors: novel series from India. Cancer Genet. Cytogenet. 198, 126-134 (2010).
37. Kraus, J. A., Felsberg, J., Tonn, J. C., Reifenberger, G. & Pietsch, T. Molecular genetic analysis of the TP53, PTEN, CDKN2A, EGFR, CDK4 and MDM2 tumour-associated genes in supratentorial primitive neuroectodermal tumours and glioblastomas of childhood. Neuropathol. Appl. Neurobiol. 28, 325-333 (2002).
38. Nakamura, M. et al. Molecular pathogenesis of pediatric astrocytic tumors. Neuro. Oncol. 9, 113-123 (2007).
39. Sung, T. et al. Preferential inactivation of the p53 tumor suppressor pathway and lack of EGFR amplification distinguish de novo high grade pediatric astrocytomas from de novo adult astrocytomas. Brain Pathol. 10, 249-259 (2000).
40. Suri, V. et al. Pediatric glioblastomas: a histopathological and molecular genetic study. Neuro. Oncol. 11, 274-280 (2009).
41. Beroukhim, R. et al. Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc. Natl Acad. Sci. USA 104, 20007-20012 (2007).
42. Maher, E. A. et al. Marked genomic differences characterize primary and secondary glioblastoma subtypes and identify two distinct molecular and clinical secondary glioblastoma entities. Cancer Res. 66, 11502-11513 (2006).
43. Liang, M. L. et al. Tyrosine kinase expression in pediatric high grade astrocytoma. J. Neurooncol. 87, 247-253 (2008).
44. Thorarinsdottir, H. K. et al. Protein expression of platelet-derived growth factor receptor correlates with malignant histology and PTEN with survival in childhood gliomas. Clin. Cancer Res. 14, 3386-3394 (2008).
45. Faury, D. et al. Molecular profiling identifies prognostic subgroups of pediatric glioblastoma and shows increased YB-1 expression in tumors. J. Clin. Oncol. 25, 1196-1208 (2007).
46. Haque, T. et al. Gene expression profiling from formalin-fixed paraffin-embedded tumors of pediatric glioblastoma. Clin. Cancer Res. 13, 6284-6292 (2007).
47. Phillips, H. S. et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 9, 157-173 (2006).
48. Verhaak, R. G. et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17, 98-110 (2010).
49. Gaspar, N. et al. MGMT-independent temozolomide resistance in pediatric glioblastoma cells associated with a PI3-kinase-mediated HOX/stem cell gene signature. Cancer Res. 70, 9243-9252 (2010).
50. Antonelli, M. et al. Prognostic significance of histological grading, p53 status, YKL-40 expression, and IDH1 mutations in pediatric high-grade gliomas. J. Neurooncol. 99, 209-215 (2010).
51. Sure, U. et al. Determination of p53 mutations, EGFR overexpression, and loss of p16 expression in pediatric glioblastomas. J. Neuropathol. Exp. Neurol. 56, 782-789 (1997).
52. Badhe, P. B., Chauhan, P. P. & Mehta, N. K. Brainstem gliomas\a clinicopathological study of 45 cases with p53 immunohistochemistry. Indian J. Cancer 41, 170-174 (2004).
53. Ganigi, P. M., Santosh, V., Anandh, B., Chandramouli, B. A. & Sastry Kolluri, V. R. Expression of p53, EGFR, pRb and bcl-2 proteins in pediatric glioblastoma multiforme: a study of 54 patients. Pediatr. Neurosurg. 41, 292-299 (2005).
54. Pollack, I. F. et al. Expression of p53 and prognosis in children with malignant gliomas. N. Engl. J. Med. 346, 420-427 (2002).
55. Pollack, I. F. et al. The relationship between TP53 mutations and overexpression of p53 and prognosis in malignant gliomas of childhood. Cancer Res. 57, 304-309 (1997).
56. Pollack, I. F. et al. Age and TP53 mutation frequency in childhood malignant gliomas: results in a multi-institutional cohort. Cancer Res. 61, 7404-7407 (2001).
57. Pollack, I. F. et al. IDH1 mutations are common in malignant gliomas arising in adolescents: a report from the Children's Oncology Group. Childs Nerv. Syst. 27, 87-94 (2010).
58. De Carli, E., Wang, X. & Puget, S. IDH1 and IDH2 mutations in gliomas. N. Engl. J. Med. 360, 2248 (2009).
59. Dang, L. et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 465, 966 (2010).
60. Cervera, A. M., Bayley, J. P., Devilee, P. & McCreath, K. J. Inhibition of succinate dehydrogenase dysregulates histone modification in mammalian cells. Mol. Cancer 8, 89 (2009).
61. Parsons, D. W. et al. The genetic landscape of the childhood cancer medulloblastoma. Science 331, 435-439 (2011).
62. Nicolaides, T. P. et al. Targeted therapy for BRAFV600E malignant astrocytoma. Clin. Cancer Res. 17, 7595-7604 (2011).
63. Raabe, E. H. et al. BRAF activation induces transformation and then senescence in human neural stem cells: a pilocytic astrocytoma model. Clin. Cancer Res. 17, 3590-3599 (2011).
64. Jacob, K. et al. Genetic aberrations leading to MAPK pathway activation mediate oncogene-induced senescence in sporadic pilocytic astrocytomas. Clin. Cancer Res. 17, 4650-4660 (2011).
65. Puget, S. et al. Mesenchymal transition and PDGFRA amplification/mutation are key distinct oncogenic events in pediatric diffuse intrinsic pontine gliomas. PLoS ONE 7, e30313 (2012).
66. Roujeau, T. et al. Stereotactic biopsy of diffuse pontine lesions in children. J. Neurosurg. 107 (Suppl. 1), 1-4 (2007).
67. Broniscer, A. et al. Prospective collection of tissue samples at autopsy in children with diffuse intrinsic pontine glioma. Cancer 116, 4632-4637 (2010).
68. Paugh, B. S. et al. Genome-wide analyses identify recurrent amplifications of receptor tyrosine kinases and cell-cycle regulatory genes in diffuse intrinsic pontine glioma. J. Clin. Oncol. 29, 3999-4006 (2011).
69. Warren, K. E. et al. Genomic aberrations in pediatric diffuse intrinsic pontine gliomas. Neuro. Oncol. 14, 326-332 (2011).
70. Grill, J. et al. Critical oncogenic mutations in newly diagnosed pediatric diffuse intrinsic pontine glioma. Pediatr. Blood Cancer 58, 489-491 (2012).
71. Becher, O. J. et al. Preclinical evaluation of radiation and perifosine in a genetically and histologically accurate model of brainstem glioma. Cancer Res. 70, 2548-2557 (2010).
72. Monje, M. et al. Hedgehog-responsive candidate cell of origin for diffuse intrinsic pontine glioma. Proc. Natl Acad. Sci. USA 108, 4453-4458 (2011).
73. Gibson, P. et al. Subtypes of medulloblastoma have distinct developmental origins. Nature 468, 1095-1099 (2010).
74. Liu, C. et al. Mosaic analysis with double markers reveals tumor cell of origin in glioma. Cell 146, 209-221 (2011).
75. Costa, B. M. et al. Reversing HOXA9 oncogene activation by PI3K inhibition: epigenetic mechanism and prognostic significance in human glioblastoma. Cancer Res. 70, 453-462 (2010).
76. Murat, A. et al. Stem cell-related "self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. J. Clin. Oncol. 26, 3015-3024 (2008)
77. Prognostic factors for high-grade malignant glioma: development of a prognostic index. A Report of the Medical Research Council Brain Tumour Working Party. J. Neurooncol. 9, 47-55 (1990).
78. Wu, W. et al. Joint NCCTG and NABTC prognostic factors analysis for high-grade recurrent glioma. Neuro. Oncol. 12, 164-172 (2010).
79. Grigsb y, P. W., Thomas, P. R., Schwartz, H. G. & Fineberg, B. B. Multivariate analysis of prognostic factors in pediatric and adult thalamic and brainstem tumors. Int. J. Radiat. Oncol. Biol. Phys. 16, 649-655 (1989).
80. Winger, M. J., Macdonald, D. R. & Cairncross, J. G. Supratentorial anaplastic gliomas in adults. The prognostic importance of extent of resection and prior low-grade glioma. J. Neurosurg. 71, 487-493 (1989).
81. Wisoff, J. H. et al. Current neurosurgical management and the impact of the extent of resection in the treatment of malignant gliomas of childhood: a report of the Children's Cancer Group trial no. CCG-945. J. Neurosurg. 89, 52-59 (1998).
82. Albright, A. L. et al. Magnetic resonance scans should replace biopsies for the diagnosis of diffuse brain stem gliomas: a report from the Children's Cancer Group. Neurosurgery 33, 1026-1029; discussion 1029-1030 (1993).
83. Hargrave, D. Pontine glioma. To biopsy or not to biopsy: that is the question. Br. J. Neurosurg. 22, 624 (2008).
84. MacDonald, T. J. Diffuse intrinsic pontine glioma (DIPG): time to biopsy again? Pediatr. Blood Cancer 58, 487-488 (2012).
85. Laperriere, N., Zuraw, L. & Cairncross, G. Cancer Care Ontario Practice Guidelines Initiative Neuro-Oncology Disease Site Group. Radiotherapy for newly diagnosed malignant glioma in adults: a systematic review. Radiother. Oncol. 64, 259-273 (2002).
86. Thomas, R. et al. Hypofractionated radiotherapy as palliative treatment in poor prognosis patients with high grade glioma. Radiother. Oncol. 33, 113-116 (1994).
87. Janssens, G. O. et al. The role of hypofractionation radiotherapy for diffuse intrinsic brainstem glioma in children: a pilot study. Int. J. Radiat. Oncol. Biol. Phys. 73, 722-726 (2009).
88. Fine, H. A., Dear, K. B., Loeffler, J. S., Black, P. M. & Canellos, G. P. Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 71, 2585-2597 (1993).
89. Stupp, R. et al. Changing paradigms-an update on the multidisciplinary management of malignant glioma. Oncologist 11, 165-180 (2006).
90. Levin, V. A. Chemotherapy for brain tumors of astrocytic and oligodendroglial lineage: the past decade and where we are heading. Neuro. Oncol. 1, 69-80 (1999).
91. Pollack, I. F., Boyett, J. M. & Finlay, J. L. Chemotherapy for high-grade gliomas of childhood. Childs Nerv. Syst. 15, 529-544 (1999).
92. Galanis, E. & Buckner, J. Chemotherapy for high-grade gliomas. Br. J. Cancer 82, 1371-1380 (2000).
93. Sposto, R. et al. The effectiveness of chemotherapy for treatment of high grade astrocytoma in children: results of a randomized trial. A report from the Childrens Cancer Study Group. J. Neurooncol. 7, 165-177 (1989).
94. Jenkin, R. D. et al. Brain-stem tumors in childhood: a prospective randomized trial of irradiation with and without adjuvant CCNU, VCR, and prednisone. A report of the Childrens Cancer Study Group. J. Neurosurg. 66, 227-233 (1987).
95. Pollack, I. F. et al. The influence of central review on outcome associations in childhood malignant gliomas: results from the CCG-945 experience. Neuro. Oncol. 5, 197-207 (2003).
96. Chastagner, P. et al. Outcome of children treated with preradiation chemotherapy for a high-grade glioma: results of a French Society of Pediatric Oncology (SFOP) Pilot Study. Pediatr. Blood Cancer 49, 803-807 (2007).
97. Gilles, F. H. et al. Pathologist interobserver variability of histologic features in childhood brain tumors: results from the CCG-945 study. Pediatr. Dev. Pathol. 11, 108-117 (2008).
98. Stupp, R. et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352, 987-996 (2005).
99. Stupp, R. et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 10, 459-466 (2009).
100. Cohen, K. J. et al. T e m ozolomide in the treatment of high-grade gliomas in children: a report from the Children's Oncology Group. Neuro. Oncol. 13, 317-323 (2011).
101. Cohen, K. J. et al. Temozolomide in the treatment of children with newly diagnosed diffuse intrinsic pontine gliomas: a report from the Children's Oncology Group. Neuro. Oncol. 13, 410-416 (2011).
102. Chassot, A. et al. Radiotherapy with concurrent and adjuvant temozolomide in children with newly diagnosed diffuse intrinsic pontine glioma. J. Neurooncol. 106, 399-407 (2012).
103. Duffner, P. K. et al. The treatment of malignant brain tumors in infants and very young children: an update of the Pediatric Oncology Group experience. Neuro. Oncol. 1, 152-161 (1999).
104. Dufour, C. et al. High-grade glioma in children under 5 years of age: a chemotherapy only approach with the BBSFOP protocol. Eur. J. Cancer 42, 2939-2945 (2006).
105. Szerlip, N. J. et al. Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response. Proc. Natl Acad. Sci. USA 109, 3041-3046 (2012).
106. Little, S. E. et al. Receptor tyrosine kinase genes amplified in glioblastoma exhibit a mutual exclusivity in variable proportions reflective of individual tumor heterogeneity. Cancer Res. 72, 1614-1620 (2012).
107. Snuderl, M. et al. Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma. Cancer Cell 20, 810-817 (2011).
108. Yap, T. A. et al. Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises. Curr. Opin. Pharmacol. 8, 393-412 (2008).
109. Bielen, A. et al. Enhanced efficacy of IGF1R inhibition in pediatric glioblastoma by combinatorial targeting of PDGFRα/β. Mol. Cancer Ther. 10, 1407-1418 (2011).
110. Pitter, K. L. et al. Perifosine and CCI 779 co-operate to induce cell death and decrease proliferation in PTEN-intact and PTEN-deficient PDGF-driven murine glioblastoma. PLoS ONE 6, e14545 (2011).
111. Gerstner, E. R. et al. Antiangiogenic agents for the treatment of glioblastoma. Expert Opin. Investig. Drugs 16, 1895-1908 (2007).
112. Mellinghoff, I. K., Lassman, A. B. & Wen, P. Y. Signal transduction inhibitors and antiangiogenic therapies for malignant glioma. Glia 59, 1205-1212 (2011).
113. van Vuurden, D. G. et al. PARP inhibition sensitizes childhood high grade glioma, medulloblastoma and ependymoma to radiation. Oncotarget 2, 984-996 (2011).
114. Smith, S. J. et al. Pediatric high-grade glioma: identification of poly(ADP-ribose) polymerase as a potential therapeutic target. Neuro. Oncol. 13, 1171-1177 (2011).
115. Thomas, A. A., Ernstoff, M. S. & Fadul, C. E. Immunotherapy for the treatment of glioblastoma. Cancer J. 18, 59-68 (2012).
116. Rutkowski, S. et al. Surger y and adjuvant dendritic cell-based tumour vaccination for patients with relapsed malignant glioma, a feasibility study. Br. J. Cancer 91, 1656-1662 (2004).
117. Zhou, J., Atsina, K. B., Himes, B. T., Strohbehn, G. W. & Saltzman, W. M. Novel delivery strategies for glioblastoma. Cancer J. 18, 89-99 (2012).
118. Chow, L. M. & Baker, S. J. Capturing the molecular and biological diversity of high-grade astrocytoma in genetically engineered mouse models. Oncotarget 3, 67-77 (2012).
119. Eglen, R. M., Gilchrist, A. & Reisine, T. The use of immortalized cell lines in GPCR screening: the good, bad and ugly. Comb. Chem. High Throughput Screen. 11, 560-565 (2008).
120. Singh, S. K. et al. Identification of a cancer stem cell in human brain tumors. Cancer Res. 63, 5821-5828 (2003).
121. Singh, S. K. et al. Identification of human brain tumour initiating cells. Nature 432, 396-401 (2004).
122. De Witt Hamer, P. C. et al. The genomic profile of human malignant glioma is altered early in primary cell culture and preserved in spheroids. Oncogene 27, 2091-2096 (2008).
123. Neale, G. et al. Molecular characterization of the pediatric preclinical testing panel. Clin. Cancer Res. 14, 4572-4583 (2008).
124. Shu, Q. et al. Direct orthotopic transplantation of fresh surgical specimen preserves CD133+ tumor cells in clinically relevant mouse models of medulloblastoma and glioma. Stem Cells 26, 1414-1424 (2008).
125. Singh, S. K., Clarke, I. D., Hide, T. & Dirks, P. B. Cancer stem cells in nervous system tumors. Oncogene 23, 7267-7273 (2004).
126. Thirant, C. et al. Clinical relevance of tumor cells with stem-like properties in pediatric brain tumors. PLoS ONE 6, e16375 (2011).
127. Fael Al-Mayhani, T. M. et al. An efficient method for derivation and propagation of glioblastoma cell lines that conserves the molecular profile of their original tumours. J. Neurosci. Methods 176, 192-199 (2009).
128. Pollard, S. M. et al. Glioma stem cell lines expanded in adherent culture have tumor-specific phenotypes and are suitable for chemical and genetic screens. Cell Stem Cell 4, 568-580 (2009).
129. Lee, J. et al. Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell 9, 391-403 (2006).
130. Hovinga, K. E. et al. Inhibition of notch signaling in glioblastoma targets cancer stem cells via an endothelial cell intermediate. Stem Cells 28, 1019-1029 (2010).
131. Houghton, P. J. et al. The pediatric preclinical testing program: description of models and early testing results. Pediatr. Blood Cancer 49, 928-940 (2007).
132. Maris, J. M. et al. Initial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing program. Pediatr. Blood Cancer 50, 581-587 (2008).
133. Kolb, E. A. et al. Combination testing (stage 2) of the Anti-IGF-1 receptor antibody IMC-A12 with rapamycin by the pediatric preclinical testing program. Pediatr. Blood Cancer 58, 729-735 (2012).
134. Morton, C. L. et al. Combination testing of cediranib (AZD2171) against childhood cancer models by the pediatric preclinical testing program. Pediatr. Blood Cancer 58, 566-571 (2012).
135. Claes, A., Idema, A. J. & Wesseling, P. Diffuse glioma growth: a guerilla war. Acta Neuropathol. 114, 443-458 (2007).
136. Caretti, V. et al. Monitoring of tumor growth and post-irradiation recurrence in a diffuse intrinsic pontine glioma mouse model. Brain Pathol. 21, 441-451 (2011).
137. Aoki, Y. et al. An experimental xenograft mouse model of diffuse pontine glioma designed for therapeutic testing. J. Neurooncol. 108, 29-35 (2012).
138. Hashizume, R. et al. A human brainstem glioma xenograft model enabled for bioluminescence imaging. J. Neurooncol. 96, 151-159 (2010).
139. Hambardzumyan, D., Parada, L. F., Holland, E. C. & Charest, A. Genetic modeling of gliomas in mice: new tools to tackle old problems. Glia 59, 1155-1168 (2011).
140. Heyer, J., Kwong, L. N., Lowe, S. W. & Chin, L. Non-germline genetically engineered mouse models for translational cancer research. Nat. Rev. Cancer 10, 470-480 (2010).
141. Chow, L. M. et al. Cooperativity within and among Pten, p53, and Rb pathways induces high-grade astrocytoma in adult brain. Cancer Cell 19, 305-316 (2011).
142. Poisson, M., Péréon, Y., Chiras, J. & Delattre, J. Y. Treatment of recurrent malignant supratentorial gliomas with carboplatin (CBDCA). J. Neurooncol. 10, 139-144 (1991).
143. Gaynon, P. S. et al. Carboplatin in childhood brain tumors. A Children's Cancer Study Group phase II trial. Cancer 66, 2465-2469 (1990).
144. Stewart, D. J., O'Bryan, R. M., Al-Sarraf, M., Costanzi, J. J. & Oishi, N. Phase II study of cisplatin in recurrent astrocytomas in adults: a Southwest Oncology Group Study. J. Neurooncol. 1, 145-147 (1983).
145. Walker, R. W. & Allen, J. C. Cisplatin in the treatment of recurrent childhood primary brain tumors. J. Clin. Oncol. 6, 62-66 (1988).
146. Komp, D. M., Land, V. J., Nitschke, R., Cangir, A. & Dyment, P. 5-[3,3-Bis(2-chloroethyl)-1-triazeno] imidazole-4-carboxamide (NSC-82196) in the treatment of childhood malignancy. Cancer Chemother. Rep. 59, 371-376 (1975).
147. Levin, V. A. et al. PCNU treatment for recurrent malignant gliomas. Cancer Treat. Rep. 68, 969-973 (1984).
148. Levin, V. A. & Wilson, C. B. Nitrosourea chemotherapy for primary malignant gliomas. Cancer Treat. Rep. 60, 719-724 (1976).
149. Allen, J. C., Hancock, C., Walker, R. & Tan, C. PCNU and recurrent childhood brain tumors. J. Neurooncol. 5, 241-244 (1987).
150. Fulton, D., Urtasun, R. & Forsyth, P. Phase II study of prolonged oral therapy with etoposide (VP16) for patients with recurrent malignant glioma. J. Neurooncol. 27, 149-155 (1996).
151. Chamberlain, M. C. Recurrent brainstem gliomas treated with oral VP-16. J. Neurooncol. 15, 133-139 (1993).
152. Chamberlain, M. C. Recurrent supratentorial malignant gliomas in children. Long-term salvage therapy with oral etoposide. Arch. Neurol. 54, 554-558 (1997).
153. Elliott, T. E. et al. Phase II study of ifosfamide with mesna in adult patients with recurrent diffuse astrocytoma. J. Neurooncol. 10, 27-30 (1991).
154. Chastagner, P. et al. Phase II study of ifosfamide in childhood brain tumors: a report by the French Society of Pediatric Oncology (SFOP). Med. Pediatr. Oncol. 21, 49-53 (1993).
155. Turner, C. D. et al. Phase II study of irinotecan (CPT-11) in children with high-risk malignant brain tumors: the Duke experience. Neuro. Oncol. 4, 102-108 (2002).
156. Friedman, H. S. et al. Irinotecan therapy in adults with recurrent or progressive malignant glioma. J. Clin. Oncol. 17, 1516-1525 (1999).
157. Prados, M. D. et al. A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. Neuro. Oncol. 8, 189-193 (2006).
158. Bomgaars, L. R. et al. Phase II trial of irinotecan in children with refractory solid tumors: a Children's Oncology Group Study. J. Clin. Oncol. 25, 4622-4627 (2007).
159. Bower, M. et al. Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma. Cancer Chemother. Pharmacol. 40, 484-488 (1997).
160. Brandes, A. A. et al. Temozolomide as a second-line systemic regimen in recurrent high-grade glioma: a phase II study. Ann. Oncol. 12, 255-257 (2001).
161. Brada, M. et al. Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. Ann. Oncol. 12, 259-266 (2001).
162. Lashford, L. S. et al. Temozolomide in malignant gliomas of childhood: a United Kingdom Children's Cancer Study Group and French Society for Pediatric Oncology Intergroup Study. J. Clin. Oncol. 20, 4684-4691 (2002).
163. Nicholson, H. S. et al. Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group. Cancer 110, 1542-1550 (2007).
164. Ruggiero, A. et al. Phase II trial of temozolomide in children with recurrent high-grade glioma. J. Neurooncol. 77, 89-94 (2006).
165. De Witt Hamer, P. C. Small molecule kinase inhibitors in glioblastoma: a systematic review of clinical studies. Neuro. Oncol. 12, 304-316 (2010).
166. Broniscer, A. et al. Phase I and pharmacokinetic studies of erlotinib administered concurrently with radiotherapy for children, adolescents, and young adults with high-grade glioma. Clin. Cancer Res. 15, 701-707 (2009).
167. Geyer, J. R. et al. A phase I and biology study of gefitinib and radiation in children with newly diagnosed brain stem gliomas or supratentorial malignant gliomas. Eur. J. Cancer 46, 3287-3293 (2010).
168. Pollack, I. F. et al. A phase II study of gefitinib and irradiation in children with newly diagnosed brainstem gliomas: a report from the Pediatric Brain Tumor Consortium. Neuro. Oncol. 13, 290-297 (2011).
169. Massimino, M., Bode, U., Biassoni, V. & Fleischhack, G. Nimotuzumab for pediatric diffuse intrinsic pontine gliomas. Expert Opin. Biol. Ther. 11, 247-256 (2011).
170. Lam, C., Bouffet, E. & Bartels, U. Nimotuzumab in pediatric glioma. Future Oncol. 5, 1349-1361 (2009).
171. Pollack, I. F. et al. Phase I trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas: a Pediatric Brain Tumor Consortium report. Neuro. Oncol. 9, 145-160 (2007).
172. Baruchel, S. et al. A Canadian paediatric brain tumour consortium (CPBTC) phase II molecularly targeted study of imatinib in recurrent and refractory paediatric central nervous system tumours. Eur. J. Cancer 45, 2352-2359 (2009).
173. Broniscer, A. et al. Phase I study of vandetanib during and after radiotherapy in children with diffuse intrinsic pontine glioma. J. Clin. Oncol. 28, 4762-4768 (2010).
174. Gururangan, S. et al. Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study. J. Clin. Oncol. 28, 3069-3075 (2010).
175. Geoerger, B. et al. Phase II trial of temsirolimus in children with high-grade glioma, neuroblastoma and rhabdomyosarcoma. Eur. J. Cancer 48, 253-262 (2012).
176. Haas-Kogan, D. A. et al. Phase I trial of tipifarnib in children with newly diagnosed intrinsic diffuse brainstem glioma. Neuro. Oncol. 10, 341-347 (2008).